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Abstract The previous clinical studies have demon-
strated tocilizumab monotherapy to be highly eVective in
rheumatoid arthritis (RA). The objectives of the present
article are to report the eYcacy and safety of tocilizumab in
patients with active RA in real clinical practice. In total, 61
patients with RA were treated with tocilizumab. Any
comorbidities they had, especially infections, were treated
thoroughly before they were given the drug. We provided
guidance on infection control and prevention. Mean age of
the patients was 60.9 § 12.4 years, and their mean disease
duration 10.9 § 9.2 years. The patients remained on ste-
roids, methotrexate, and tacrolimus as before, but were
taken oV any other drugs they had been using prior to the
treatment. Mean of the 28-joint disease activity score using
erythrocyte sedimentation rate was 4.75 § 1.15 initially
and fell to 2.21 § 0.97 after two doses (n = 50). After four
doses, the remission rate was 83.8% (31/37). All patients
responded well to the therapy and there was no decrease in
the eYcacy of tocilizumab during the treatment. Even in the
real clinical setting, treatment with tocilizumab can rapidly
induce remission in RA in a high proportion of patients and
is generally safe and well tolerated. Tocilizumab would
seem to be promising as a Wrst-line choice for the treatment
of RA.
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Introduction
The characteristic pathophysiology in rheumatoid arthritis
(RA) is the destruction of bone and cartilage due to persis-
tent synovitis of unknown etiology. Large quantities of
inXammatory cytokines such as tumor necrosis factor
(TNF), interleukin-1 (IL-1), and interleukin-6 (IL-6) are
produced in inXamed synovial membranes, and these are
deeply involved in the spread and persistence of the inXam-
mation [1]. The basic concept behind anti-cytokine thera-
pies is to trap these inXammatory cytokines using
biological agents such as antibodies or receptors and so
block their activity.
TNF inhibitors are a recent development in this Weld and
have been demonstrated to be useful in the treatment of RA
[2]. The progression of bone destruction can be halted by
using them in combination with methotrexate (MTX) [3].
However, they may also increase susceptibility to serious
infections such as tuberculosis. Even when MTX is used
concomitantly, there are also instances of primary non-
responders, mid-treatment secondary non-responders
(escape cases), and inadequate responders, indicating that
TNF is of little or no relevance to the condition in some
patients. Drugs able to overcome the limitations of anti-
TNF therapy have thus been sought.
Tocilizumab (TCZ) is a humanized monoclonal antibody
against IL-6 receptors and inhibits binding between IL-6
and IL-6 receptors [4, 5]. It has been shown to be useful
against RA in the clinical trials conducted to date. In the
SATORI study, it gave signiWcantly higher improvement
rates than MTX [6], in the OPTION study, clinical eYcacy
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was higher with MTX + TCZ than with MTX alone [7], in
the SAMURAI study, it was eVective as monotherapy for
controlling the progression of bone and joint destruction
[8], and in the STREAM study, it provided high levels of
eYcacy and continuity of response as long-term mono-
therapy [9]. Mean 28-joint disease activity score using
erythrocyte sedimentation rate (DAS28ESR) at baseline
had been elevated in the clinical trials (6.1 in the SATORI
and 6.5 in the SAMURAI study), and the remission rate
achieved was about 40% at 24 weeks in the SATORI study
and 59% at 52 weeks in the SAMURAI study.
TCZ was approved for marketing in Japan for use in
patients with RA on 16 April 2008. This was the Wrst time
that the drug had been approved anywhere so there are still
almost no reports of treatment outcomes in real clinical
practice. We evaluated our clinical experience with TCZ
for therapy of RA. Here, we report the clinical eYcacy and
safety of TCZ in the treatment of patients with active RA in
real-world settings.
Patients and methods
Patients
The subjects of this analysis were patients who met the
1987 revised criteria for the classiWcation of RA from the
American College of Rheumatology (ACR) and who had
active disease with the DAS28ESR of 2.6 or over. Patients
were included in the analysis if they started treatment with
TCZ for the Wrst time in the 11 months between 16 April
2008 (the time of insurance approval in Japan) and 15
March 2009 and they received TCZ at least twice during
this time. Their demographics, baseline characteristics, and
drug use prior to the treatment are shown in Table 1. The
criteria for exclusion from the analysis set were as follows:
(i) autoimmune disease comorbidities except Sjögren’s
syndrome and Hashimoto’s disease, (ii) functional class IV
based on the Steinbrocker criteria, (iii) presence of active
infection, (iv) pregnancy, (v) drug poisoning, including
alcohol, (vi) lymphocyte count ·500 cells/l, and (vii) pos-
itive serum -D-glucan.
Screening
To reduce adverse events, any comorbidity was treated or
controlled as well as possible before giving TCZ. All
patients had a thoracic CT scan and were tested for the
tuberculin reaction, anti-streptolysin O (ASO), anti-strepto-
kinase (ASK), treponema pallidum haemagglutination
(TPHA), hepatitis B surface antigen, anti-hepatitis C virus
antibody, and -D-glucan to screen for infections. If tooth
plaque or caries were present, we arranged for assessment
and treatment by a dentist, including for the presence of
apical periodontitis. If chronic rhinorrhea or nasal blockage
was seen, the patient was assessed and treated by an otolar-
yngologist. Patients were asked whether they had hemor-
rhoids.
Handling of previous medications
Among the various therapies being used by the patients in the
three months before they received TCZ, inXiximab were dis-
continued at least one-month before and etanercept at least
4 days before the new treatment commenced. Salazosulfa-
pyridine, bucillamine, sodium aurothiomalate, and mizori-
bine were discontinued upon initiating TCZ. The patients
stayed on methotrexate, tacrolimus, and steroids at the same
dose levels as before at least until dose 3 of TCZ. There were
no users of adalimumab, auranoWn, D-penicillamine, hydroxy-
chloroquine, minocycline, or lobenzarit disodium, nor had
any patient undergone granulocytapheresis therapy.
Administration of TCZ
The method of administering TCZ that has received insur-
ance approval in Japan is a continuous infusion of a dose of
Table 1 Patient demographics, clinical characteristics, and previous
medications at baseline
The values shown are mean § SD unless otherwise indicated
CRP only calculated from data for 60 patients
‘Previous medications’ denotes drugs used in the 3 months before
administration of TCZ
‘Other DMARDs’ were sodium aurothiomalate, bucillamine, sala-
zosulfapyridine, and mizoribine. These were discontinued on initiating
TCZ
Demographics
Age (years) 60.9 § 12.4
Male:Female 12:49
Clinical characteristics
RA duration (years) 10.9 § 9.2
Steinbrocker Class (I, II, III, IV) 25, 25, 11, 0
Steinbrocker Stage (I, II, III, IV) 11, 9, 5, 36
Tender joint count (0–28) 5.3 § 4.9
Swollen joint count (0–28) 4.0 § 3.5
ESR (mm/h) 39.8 § 25.6
CRP (mg/l) 17 § 17
DAS28 (4/ESR) 4.75 § 1.15
Previous medications
Prednisolone (n=, mg/day) 45, 3.95 § 3.12
Anti-TNF (n=) 6
MTX (n=) 21
Tacrolimus (n=) 5
Other DMARDs (n=) 28Rheumatol Int (2010) 30:1041–1048 1043
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8 mg/kg over a period of at least 1 h once every 4 weeks.
No conditions have been set for Wnishing treatment. The
interval between infusions was shortened to 3 weeks
between the Wrst and second infusions only, and an interval
of 4 § 1 weeks was used thereafter. Treatment was contin-
ued unless there were adverse events requiring discontinua-
tion of treatment or the patient requested that treatment be
stopped.
Patient education
We provided guidance on infection control and prevention.
We also gave lifestyle advice to try and achieve standard
body mass index (BMI).
Statistical analysis
Statistical signiWcance was determined by the two-tailed
Student’s t-test with P < 0.05 taken to indicate signiWcance.
Results
Clinical eYcacy
Mean DAS28ESR at the start of TCZ treatment in all 61
patients was 4.75 § 1.15. After two doses, mean
DAS28ESR had fallen below the remission threshold
(<2.6) to 2.21 § 0.97 and after six doses had further
improved to 1.63 § 0.71 (Fig. 1a). The clinical response
was evaluated using the European League Against Rheu-
matism (EULAR) response criteria. Thirty-one out of 37
patients (83.8%), who had received four doses, had
achieved remission with treatment response of good in
97.3%, moderate in 2.7%, and no cases of no response
(Fig. 1b). The no response seen beyond Wve doses was due
to a rise in DAS28ESR associated with a temporary deteri-
oration in symptoms due to factors other than RA and did
not represent secondary non-response. To date, no patient
has discontinued the treatment due to lack of response.
The doses of concomitant drugs after starting treatment
with TCZ were examined in 18 patients who received TCZ
at least six times (for approximately 6 months) in the obser-
vation period. Of these 18 patients, 16 used steroids, 5 used
MTX, and none used tacrolimus. In all Wve patients who
used MTX, tapering was completed after remission, but RA
did not Xare up. The steroid dose was decreased slowly to
avoid steroid withdrawal syndrome. In the 16 patients who
used steroids, the mean steroid dose was 5.4 mg/day (pred-
nisolone equivalent) at the start of treatment with TCZ and
4.1 mg/day at the end of the observation period. In all Wve
patients who were using tacrolimus at the start of treatment
with TCZ, it was possible to reduce the dose of tacrolimus
or to Wnish treatment with tacrolimus in the observation
period, even though the patients had received TCZ not
more than Wve times.
Next, we investigated diVerences in the therapeutic
eYcacy of TCZ depending on their baseline level of disease
activity. We classiWed the patients based on DAS28ESR
into a high-activity group at >5.1 (n = 23), a moderate-
activity group at 3.2–5.1 (n = 32), and a low-activity group
at <3.2 (n = 6). Although mean DAS28ESR had been
5.87 § 0.75 in the high-activity group before treatment
with TCZ, this improved rapidly and went below the remis-
sion threshold to 2.27 § 0.98 (n = 16) after three doses
(after 11–12 weeks; Fig. 2a). After four doses, good
response was recorded for 93.8% (15/16) of the patients
and the remission rate reached 81.3% (13/16) (Fig. 2b). In
the moderate and low disease activity groups, mean
DAS28ESR of 4.28 § 0.57 (n = 32) and 2.91 § 0.22
(n = 6), respectively, at baseline fell below the remission
threshold after one dose to 2.49 § 0.88 (n = 32) and
1.87 § 0.96 (n = 6), respectively (Fig. 2a). Hundred per-
cent of those (n = 16) with moderate disease activity
showed good response after four doses, with a remission
rate of 81.3% (13/16) (Fig. 2c). In the low-activity group,
Wve of the six patients went into remission after the Wrst
dose and the other one after three doses. TCZ proved to be
very eVective regardless of baseline disease activity.
Fig. 1 a Change in DAS28ESR in all patients. Mean values shown.
Bars indicate SD. “n” indicates the number of patients. Since each
patient was treated with TCZ starting on the diVerent dates, “n” in each
“doses”, indicated in abscissa, decreases dependent on the date of the
Wrst dose. b Change in response and remission rate in all patients
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With age, physical capacity generally declines and resis-
tance to infections diminishes, so that there is often more
concurrent disease as well. In the joints especially, one sees
an increasing frequency of pain or swelling associated with
osteoarthritis. To investigate whether such factors would
produce diVerences in the eYcacy or safety of TCZ ther-
apy, we divided the patients into an elderly group aged 65
and over (n = 24, mean age 72.5 § 5.3, mean disease
duration 11.5 § 10.8 years) and non-elderly group aged
less than 65 (n = 37, mean age 53.2 § 9.5, mean disease
duration 10.0 § 7.6 years) in accordance with WHO
classiWcation and compared the two groups. Mean baseline
DAS28ESR was 4.93 § 1.13 in the elderly and 4.63 § 1.15
in the non-elderly group (P = 0.324) (Fig. 3a). After two
doses, mean DAS28ESR fell to 2.36 § 1.13 (n =1 8 )  a n d
2.12 § 0.87 (n = 32), respectively, both below the remis-
sion threshold. At the 4-dose point, good response had been
demonstrated in 100% of those (n = 25) in the non-elderly
group, with remission of 88.0% (22/25) (Fig. 3b), and in
the elderly group, there had been a good response in 91.7%
(11/12) with remission of 75.0% (9/12) (Fig. 3c). No sig-
niWcant diVerence between mean DAS28ESR was observed
between both groups (non-elderly 1.66 versus elderly 2.21;
P = 0.138). TCZ thus provided similarly high success rates
in both groups.
Fig. 2 a Change in DAS28ESR by disease activity at baseline.
Patients were divided into three groups according to their DAS28ESR
score into high disease activity (DAS28ESR > 5.1), moderate disease
activity (3.2–5.1), and low disease activity (2.6 to <3.2). Mean values
shown. Bars indicate SD. b Change in response and remission rate in
DAS28ESR > 5.1 group. “n” indicates the number of patients. (See the
legend for Fig. 1.)  c Change in response and remission rate in
DAS28ESR 3.2–5.1 group
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Fig. 3 a Change in DAS28ESR by age group. Mean values shown.
Bars indicate SD. b Change in response and remission rate in those
aged <65. “n” indicates the number of patients. (See the legend for
Fig. 1.) c Change in response and remission rate in those aged 65 and
over
0
1
2
3
4
5
6
7
12345678
D
A
S
2
8
-
E
S
R
Over 65 years old
Below 65 years old
TCZ (doses)
pre
A
B
C
1
37
2
32
3
27
4
25
5
19
6
14
7
11
8
9
P
a
t
i
e
n
t
s
 
(
%
)
R
e
m
i
s
s
i
o
n
 
(
%
)
100
80
60
40
20
0
TCZ (doses)
n=
no response
moderate response
good response
remission
100
80
60
40
20
0
1
24
2
18
3
15
4
12
5
10
6
4
7
2
8
2
P
a
t
i
e
n
t
s
 
(
%
)
R
e
m
i
s
s
i
o
n
 
(
%
)
TCZ (doses)
n=
100
80
60
40
20
0
100
80
60
40
20
0
no response
moderate response
good response
remissionRheumatol Int (2010) 30:1041–1048 1045
123
Safety
A total of 27 adverse events occurred in 24 of the 61
patients and these are listed separately for the non-elderly
group and elderly group in Table 2. Taking the causal rela-
tionships discussed below, there seemed to be no diVerence
in adverse events between the ¸65 and <65 groups.
Anxiety disorders, palpitations, and cystitis had been
seen occasionally before exposure to TCZ. Leukocytopenia
reversed upon discontinuing the MTX that the patient had
remained on since before treatment and giving folic acid.
From the symptoms and clinical course, the nasopharyngi-
tis and gastroenteritis seemed to be viral infections preva-
lent at the time. The elevated CRP and ESR appeared to be
linked to inXammation from concurrent hemorrhoids. We
established subsequently that a rash on the right forearm
had been due to an alcohol-based disinfectant. Epigastric
pain disappeared upon discontinuing the nonsteroidal
anti-inXammatory drugs that the patient had been using and
giving a proton pump inhibitor. We carried out upper gastro-
intestinal investigations and abdominal ultrasound on a
patient who complained of abdominal discomfort but found
nothing unusual. Although we were unable to identify the
cause, it disappeared in a little while.
Drug-related infusion reactions were observed as eight
events in Wve patients. The adverse events seen during infu-
sion were transient back pain, lumbar discomfort, and
ischial pain. These all appeared a few minutes into infusion
and disappeared within a few minutes. There was nothing
abnormal as regards body temperature, blood pressure, and
pulse, nor was it the case that they occurred at each infu-
sion. The patients were negative for IgE anti-TCZ antibod-
ies. One patient suVered a transient mild choking sensation
during the night after the Wrst dose, but this did not recur at
the time of the second and the patient was negative for IgE
anti-TCZ antibodies as well.
Five serious adverse events occurred in total. Two
patients developed pneumonia. One of these was a 60-year-
old woman with old tuberculosis and bronchiectasis as
comorbidities. She showed a slight rise over her previous
level of hemosputum, and bacterial pneumonia appeared
subsequently. The other patient was an 80-year-old woman
suspected to have pneumonia due to Chlamydia pneumo-
niae. Both recovered with treatment. The case of speech
disorder was due to motor impairment of the tongue, but a
cranial MRI scan failed to identify anything unusual. This
is still being investigated as possible RA damage to the cer-
vical vertebrae. The patient who died due to cerebellar
infarction was elderly, at 82 years old, and had once
suVered strokes in the past. The patient in whom malignant
lymphoma became patent is considered in the Discussion.
All except the two patients who suVered cerebellar infarc-
tion and malignant lymphoma are continuing to be treated
with TCZ.
Laboratory Wndings
CRP virtually normalized in all patients after the Wrst dose
of TCZ (1.74 § 1.7 ! 0.23 § 0.37 mg/dl). ESR likewise
normalized quickly after the Wrst dose (39.1 § 25.3 !
8.9 § 9.2 mm/h). Both followed a normal course after-
wards as well.
The mean leukocyte count was 8,400 § 2,990/l at base-
line, but went down to around 6,000/l after the Wrst dose.
There was no progressive fall as seen in myelosuppression
and no signiWcant increase in infections was recorded
either (Fig. 4a). Likewise, the mean platelet count of
315,000 § 74,000/l at baseline went to around 220,000/l
after the Wrst dose (Fig. 4a).
The hemoglobin level rose gradually and anemia
improved after treatment with TCZ began (Fig. 4b).
Figure 4c shows changes over time in ALT as an index
of liver function. Even though abnormal values for ALT
occurred, they were transient and all were of grade I based
on the National Cancer Institute Common Toxicity Criteria
(NCI-CTC).
Table 2 Adverse events
The values shown denote the number (%) of patients
a Serious adverse event
Age ¸65 (n = 37) Age <65 (n = 24)
Cerebellar infarctiona 1 (2.7)
Speech disordera 1 (2.7)
Nasopharyngitis 1 (2.7)
Anxiety disorder 1 (2.7)
Choking sensation 1 (4.2)
Increased hemosputum 1 (4.2)
Pneumoniaa 1 (2.7) 1 (4.2)
Palpitation 1 (4.2)
Malignant lymphomaa 1 (4.2)
Rash (right forearm) 1 (4.2)
Epigastric pain 1 (2.7)
Abdominal discomfort 1 (2.7)
Gastroenteritis 1 (2.7)
Back pain 2 (8.3)
Lumbar discomfort 2 (8.3)
Ischial pain 1 (4.2)
Cystitis 1 (2.7)
Leukocytopenia 1 (4.2)
Elevated CRP 2 (8.3)
Elevated ESR 1 (4.2)
Total 9 (24.3) 15 (62.5)1046 Rheumatol Int (2010) 30:1041–1048
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Mean total cholesterol at baseline was 203.7 § 35.6 mg/dl.
Upon treatment with TCZ, it rose slightly and stayed
around the 225 mg/dl level, but showed no continuous
increase (Fig. 4d). We gave lifestyle guidance and simply
monitored the clinical course without providing any drug
treatment at least until dose 3. We started Wve patients
whose level nevertheless exceeded 280 mg/dl on treatment
with a HMG-CoA reductase inhibitor.
Discussion
This article presents our therapeutic results for the use of
TCZ in patients with diverse medical histories in real clini-
cal practice. TCZ rapidly reduced disease activity in
patients with RA and achieved high remission rates even in
real clinical practice. A further noteworthy point was that
all 61 of the patients responded to treatment. No primary or
secondary failure has been seen and mean DAS28ESR has
remained good (1.6–1.7) in observations until now (July
2009).
The great advantage of treatment with TCZ is that a sat-
isfactory therapeutic response can be obtained by mono-
therapy [9]. As TCZ is an antibody, it has no intrinsic
chemical toxicity. The frequency of infusion reactions is
also small (7.0% in the SAMURAI study) [8]. Controlling
comorbidities and preventing infection are thus key issues
in reducing adverse events and deriving the maximum
possible therapeutic beneWt from TCZ. We screened the
patients for comorbidities, particularly infection, other than
RA before initiating treatment with TCZ and cured or con-
trolled these to the extent possible. This not only served to
reduce adverse events, but also stopped stimulation for IL-6
production from factors other than RA. For example, peri-
odontitis stimulates the expression of pro-inXammatory
cytokines such as TNF and IL-6 [10]. Non-surgical peri-
odontal therapy had a beneWcial eVect on the signs and
symptoms of RA, regardless of the medications used to
treat this condition [11].
Arthralgia due to infection is all too common and some-
times can elicit ‘reactive arthritis’ in the broad sense of the
term [12]. If RA patients have reactive arthritis as a compli-
cating factor, there is a risk of it being mistaken for treat-
ment-refractory RA. Many types of pathogen such as the
Streptococci responsible for rheumatic fever, Salmonella
and Chlamydia have been reported as causative agents in
reactive arthritis. All too often, however, it is diYcult to
identify the seat of infection. Patients in whom concomitant
infection could be ruled out were thus given a 7–14 day
course of 100 mg/day doxycycline, which is even eVective
against Chlamydia, and we monitored whether or not their
symptoms or laboratory Wndings improved as a result of
this.
Turning to patient education, as infection control, we
advised the patients about maintaining cleanliness through
hand washing and gargling and avoiding contact with
Fig. 4 Change in white blood cell counts and platelet counts (a), hemoglobin (b), alanine transaminase (c), and total cholesterol (d). Mean values
shown. Bars indicate SD. “n” indicates the number of patients. (See the legend for Fig. 1.)
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people with infections. We advised that particular attention
should be paid to the cleanliness of the mouth, nostrils, uri-
nary organs, the area around anus, and so on where patho-
gens can easily gain access. The risk of infection can be
reduced quite substantially by keeping these areas clean.
For example, ensuring good oral hygiene in nursing homes
has been shown to reduce the incidence of pneumonia and
mortality rates signiWcantly [13]. In the SAMURAI study,
nasopharyngitis was the most common adverse event in the
both groups (the control group 32.4% (47/145), the TCZ
group 35.7% (56/157)) [8]. In this report, the frequency of
infections (8.2% (5/61): 1 with nasopharyngitis, 2 with
pneumonia, 1 with gastroenteritis, and 1 with cyctitis) was
lower than found in the clinical trials regardless of the fact
that many of our patients were elderly and that the treat-
ment period had included the winter.
It is not clear yet whether TCZ treatment might inXuence
the incidence of malignancies or not. The patient with
malignant lymphoma discovered as a left axillary mass had
undergone a PET-CT scan to assess the activity of intersti-
tial pneumonia before being treated with TCZ. Although
there were no accumulations in the lungs, accumulation
was picked up in the left axillary lymph nodes. Tiny lym-
phadenopathy was found at the same site by CT scan.
Retrospectively, it may be inferred that the accumulation seen
by PET had been in the early stages of malignant lym-
phoma. Further investigation will be needed into whether
or not TCZ has any bearing on the frequency and growth
rates of malignant lymphomas.
We encountered no laboratory test abnormalities so
severe that treatment with TCZ could not continue. The
WBC and platelet counts fell following the Wrst dose to
steady levels. These matched the time courses of CRP or
ESR, and we inferred that this constituted the disappear-
ance of the additional amounts induced by stimulation from
inXammatory cytokines or inXammatory chemokines, that
is to say, their return to normal levels. It appeared that the
rise in hemoglobin had likewise resulted from the elimina-
tion of an IL-6-linked rise in hepcidin due to the action of
TCZ [14]. TCZ had no adverse eVect on the blood cell sys-
tem and rather reduced abnormalities brought about by RA.
Slight, transient rises in ALT were seen after giving TCZ.
In some patients, this improved upon discontinuing the
methotrexate they had remained on since before treatment
with TCZ. Some patients improved with diet therapy.
Weight gain was in fact often seen, and it seemed possible
that rises in ALT due to fatty liver had been involved in
patients showing normalization in ALT through diet. Total
cholesterol also showed a slight rise in many patients after
they received TCZ, as observed similarly in the results of
the clinical trials to date [6–9]. The details of the mecha-
nism whereby TCZ produces rises in cholesterol are
unclear, but in patients who improved with lifestyle
guidance including diet, this was inferred to be due to the
calorie excess.
During the clinical trials, we encountered several
patients whose arthritis had improved following the Wrst
dose but returned after 3 weeks. This suggested that the
blood level could not be maintained over the 4-week
period. We thus decided to give only the second dose after
an interval of 3 weeks following the Wrst. By doing this, not
one of our patients suVered repeat deterioration by the time
of the second dose in symptoms that had improved follow-
ing the Wrst. A shorter dose interval at the start may be
thought to be perfectly reasonable in terms of maintaining
the blood levels of biologics. In short, it seems that by giv-
ing the second dose before the blood level has had a chance
to fall, the time to remission can be reduced. We have not
seen any rise in adverse events as a result of this.
Another article describes how bone destruction in joints
that had become inXamed was demonstrated 4 months later
by MRI in about half the patients [15]. It is therefore impor-
tant to achieve remission within 4 months at least of the
onset of RA to try and ensure that bone destruction does not
set in. Based on the Wndings in this article, in which all
patients responded to treatment and a remission rate of
83.8% was achieved after four doses, it seems that by pro-
viding treatment with TCZ from the outset, the window of
opportunity for halting bone destruction in a high propor-
tion of patients will not be lost. TCZ would seem to be
promising as a Wrst-line choice for the treatment of RA.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
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